Drug executives challenge near-term AI disease-cure predictions
TechNews, citing The Wall Street Journal, reports that Anthropic CEO Dario Amodei has predicted AI could cure most human diseases within ten years, but executives from Vertex Pharmaceuticals, AstraZeneca, and Regeneron dispute near-term claims of sweeping cures or sharply shortened drug-development timelines. Vertex CEO Jeff Leiden said about 50 AI companies failed to produce a usable drug when given data on thousands of its compounds, while McKinsey senior partner Alex Devereson said current models cannot reliably predict the safety problems behind roughly one-quarter of mid-to-late-stage development failures. McKinsey data cited by TechNews shows $8.4 billion in global venture-capital and private-equity investment in AI drug development during 2025, although only a small number of AI-native biotechnology companies reached late-stage trials and none of their drugs had FDA approval.
The reported disagreement highlights the gap between AI's ability to accelerate candidate design and the biological, safety, clinical, and regulatory barriers to producing approved medicines.


Anthropic執行長阿莫迪(Dario Amodei)曾預言,AI 可望十年內治癒多數人類疾病。《華爾街日報》報導,藥廠高層並不認同,認為人體生物學太複雜,即使是超級智慧也很難破解。
福泰製藥(Vertex Pharmaceuticals)執行董事長萊登(Jeff Leiden)提到,曾有科技業領袖向他宣稱,AI將在七年內治癒九成人類疾病,他直斥這是一派胡言。萊登表示,福泰曾找來約50家AI公司分析旗下萬種藥物化合物資料,結果沒有一家成功做出可用藥物。
#Anthropic#Vertex Pharmaceuticals#AstraZeneca#Regeneron#McKinsey#Insilico Medicine#Generate Biomedicines#Eli Lilly#Nvidia#Bristol Myers Squibb#Novo Nordisk#Sanofi